Last reviewed · How we verify

NCT06106477

Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer

Recruiting now NA Last updated 13 August 2025
What this trial tests

NA trial testing Intermittent Fasting in Breast Cancer in 20 participants. Currently enrolling.

Timeline
19 July 2024
Primary endpoint
15 July 2026
15 July 2026

Quick facts

Lead sponsorMedical College of Wisconsin
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposesupportive care
Enrollment20
Start date19 July 2024
Primary completion15 July 2026
Estimated completion15 July 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Medical College of Wisconsin

Who can join

18 and older, any sex, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This single-arm study is designed to test the hypothesis that a six-month intermittent fasting (IF) intervention is feasible for patients to adhere to and improves health-related quality of life while subjects are on adjuvant endocrine therapy (AET).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Advances in Diet and Physical Activity in Breast Cancer Prevention and Treatment.
    Khalifa A, Guijarro A, Nencioni A. · · 2024 · cited 17× · PMID 39064705 · DOI 10.3390/nu16142262

Verify or expand the search:

Other trials of Intermittent Fasting

Trials testing the same drug.

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

Other Medical College of Wisconsin trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06106477.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing